2009
Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial
Abdelmalek M, Sanderson S, Angulo P, Soldevila‐Pico C, Liu C, Peter J, Keach J, Cave M, Chen T, McClain C, Lindor K. Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial. Hepatology 2009, 50: 1818-1826. PMID: 19824078, DOI: 10.1002/hep.23239.Peer-Reviewed Original ResearchConceptsNonalcoholic steatohepatitisBetaine therapyHepatic steatosisAnimal studiesNonalcoholic fatty liver disease activity scoreBiopsy-proven nonalcoholic steatohepatitisRandomized placebo-controlled trialNonalcoholic fatty liver diseaseRandomized placebo-controlled studyPosttreatment liver biopsiesDisease Activity ScorePlacebo-controlled studyPlacebo-controlled trialFatty liver diseaseElevation of insulinNovel therapeutic optionsSecond hit mechanismsOral betaineWilcoxon rank testNASH patientsLiver biopsyActivity scoreLiver diseaseRemethylation of homocysteineSteatosis grade
2005
40 THE NATURAL HISTORY OF CRYPTOGENIC CIRRHOSIS FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION: A HISTORICAL COHORT STUDY
Abdelmalek M, Mudaliar K, Liu C, Reed A, Nelson D, Asal N, Stacpoole P. 40 THE NATURAL HISTORY OF CRYPTOGENIC CIRRHOSIS FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION: A HISTORICAL COHORT STUDY. Journal Of Investigative Medicine 2005, 53: s393. DOI: 10.2310/6650.2005.00205.39.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseLiver transplantationCryptogenic cirrhosisSteatosis gradeClinical dataMean age 53Repeat liver transplantationYr post-LTFatty liver diseaseInsulin resistance syndromeCardiovascular disease deathsPost-LTPre-LTMELD scoreGlycemic controlHDL cholesterolLiver biopsyInflammatory activityLDL cholesterolLiver diseaseDisease deathsResistance syndromeSingle pathologistClinicopathologic correlationRisk factors
2004
One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection
Firpi R, Abdelmalek M, Soldevila‐Pico C, Cabrera R, Shuster J, Theriaque D, Reed A, Hemming A, Liu C, Crawford J, Nelson D. One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transplantation 2004, 10: 1240-1247. PMID: 15376304, DOI: 10.1002/lt.20238.Peer-Reviewed Original ResearchConceptsProtocol liver biopsiesRapid fibrosis progressionLiver transplant recipientsFibrosis progressionDonor ageLiver biopsyTransplant recipientsCytomegalovirus infectionUnits/yearMedian fibrosis progression rateRecurrent hepatitis C infectionHepatitis C virus infectionC virus infectionDevelopment of cirrhosisFibrosis progression rateHepatitis C infectionSurgery-related variablesRate of progressionDevelopment of fibrosisDeterminants of progressionGraft lossKnodell systemRecurrent HCVRejection episodesYear posttransplant
2003
Long‐term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti‐inflammatory effect
Nelson D, Tu Z, Soldevila‐Pico C, Abdelmalek M, Zhu H, Xu Y, Cabrera R, Liu C, Davis G. Long‐term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti‐inflammatory effect. Hepatology 2003, 38: 859-868. PMID: 14512873, DOI: 10.1002/hep.1840380412.Peer-Reviewed Original ResearchConceptsIL-10HCV RNASerum ALTCytokine productionChronic hepatitis C patientsFunctional T cell analysesSerum HCV RNA levelsHCV-specific CD4Hepatic inflammation scoresIL-10 administrationInterleukin-10 therapyPBMC cytokine productionTh2 dominant profileHCV RNA levelsHepatitis C patientsT cell analysisTh2 cytokine productionAnti-inflammatory effectsAcute flaresC patientsDisease activityMeq/mLViral burdenAdvanced fibrosisLiver biopsy